Sun Yuanbo, Xie Like, Zhang Jing, Liu Runing, Li Hanbing, Yang Yanquan, Wu Yapeng, Peng Ying, Wang Guangji, Hughes-Medlicott Natalie, Sun Jianguo
Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Research Unit of PK-PD Based Bioactive Components and Pharmacodynamic Target Discovery of Natural Medicine of Chinese Academy of Medical Sciences, China Pharmaceutical University, Nanjing, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
School of Pharmacy, University of Otago, Dunedin, New Zealand.
Drug Metab Dispos. 2025 Jan;53(1):100005. doi: 10.1124/dmd.124.001817. Epub 2024 Nov 22.
Silybin, a milk thistle extract, is a flavonolignan compound with hepatoprotective effect. It is commonly used in dietary supplements, functional foods, and nutraceuticals. However, the metabolism of silybin has not been systematically characterized in organisms to date. Therefore, we established a novel high-performance liquid chromatography quadrupole time-of-flight mass spectrometry method to analyze and identify the prototype and metabolites of silybin in rats. In total, 29 (of 32) new metabolic pathways and 56 (of 59) unreported metabolite products were detected. Moreover, we found that the liver had a high first-pass effect of 63.30% ± 13.01% for silybin, and only 1 metabolite was detected. Moreover, the metabolites identified in gastrointestinal tract possessed 88% of all unreported metabolite products (52 of 59). At the same time, the high concentration of silybin in the liver also indicated that large amounts of silybin may be accumulated in the liver instead of being metabolized. These results indicated that the primary metabolizing organ of silybin in rats was intestine rather than liver, which offers a solid chemical foundation for exploring more pharmacological effects of silybin. SIGNIFICANCE STATEMENT: This study confirmed that the primary location of metabolism of silybin in rats after intragastric administration was the gastrointestinal tract instead of the liver and that intestinal microbes were closely involved. In total, 29 (of 32) metabolism pathways and 56 (of 59) metabolites were identified for the first time in rats, to the authors' knowledge. To further study the liver disposition of silybin, its hepatic first-pass effect was determined for the first time. This work is capable of furnishing a robust material foundation for the forthcoming pharmacological investigations regarding silybin.
水飞蓟宾是一种水飞蓟提取物,是一种具有肝脏保护作用的黄酮木脂素化合物。它常用于膳食补充剂、功能性食品和营养保健品中。然而,迄今为止,水飞蓟宾在生物体中的代谢尚未得到系统表征。因此,我们建立了一种新型高效液相色谱四极杆飞行时间质谱法,用于分析和鉴定大鼠体内水飞蓟宾的原型和代谢产物。总共检测到29条(共32条)新的代谢途径和56种(共59种)未报道的代谢产物。此外,我们发现肝脏对水飞蓟宾的首过效应高达63.30%±13.01%,仅检测到1种代谢产物。而且,在胃肠道中鉴定出的代谢产物占所有未报道代谢产物的88%(59种中的52种)。同时,肝脏中水飞蓟宾的高浓度也表明大量水飞蓟宾可能在肝脏中积累而非被代谢。这些结果表明,大鼠体内水飞蓟宾的主要代谢器官是肠道而非肝脏,这为探索水飞蓟宾更多的药理作用提供了坚实的化学基础。意义声明:本研究证实,大鼠灌胃给药后水飞蓟宾的主要代谢部位是胃肠道而非肝脏,且肠道微生物密切参与其中。据作者所知,总共首次在大鼠体内鉴定出29条(共32条)代谢途径和56种(共59种)代谢产物。为进一步研究水飞蓟宾的肝脏处置情况,首次测定了其肝脏首过效应。这项工作能够为即将开展的关于水飞蓟宾的药理研究提供坚实的物质基础。